Gene
EPHA2
EPHA2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (6), Actionable biomarkers (3), Trial mentions (5), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention EPHA2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
EPHA2 has 5 trial mentions across 3 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 9 of 11,460 | 0.08% |
| 2022 | 0 of 8,285 | 0.00% | 10 of 13,598 | 0.07% |
| 2021 | 0 of 8,692 | 0.00% | 11 of 15,045 | 0.07% |
| 2020 | 0 of 7,640 | 0.00% | 8 of 14,459 | 0.06% |
| 2019 | 0 of 7,300 | 0.00% | 13 of 12,159 | 0.11% |
| 2018 | 0 of 6,927 | 0.00% | 4 of 11,854 | 0.03% |
| 2017 | 0 of 6,558 | 0.00% | 7 of 11,595 | 0.06% |
Showing 10 of 37 years.
Assay-provider ledger (6)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent Technologies | Reagent supplier | Clinical validationAnalytical validation | 1 | September 22, 2015 |
| Life Technologies | Reagent supplier | Clinical validationAnalytical validation | 1 | September 22, 2015 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 1 | September 22, 2015 |
| AB Applied Biosystems | Reagent supplier | Analytical validation | 1 | March 10, 2015 |
| R & D Systems | Reagent supplier | Clinical validation | 1 | Date unknown |
Showing 5 of 6 assay-provider companies.
Actionable biomarkers (3)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| EPHA2 (G391R) | Dasatinib | response-associated | squamous cell lung carcinoma | Cancer Genome Interpreter |
| EPHA2 (G391R) | Mtor Inhibitors | response-associated | squamous cell lung carcinoma | Cancer Genome Interpreter |
| EPHA2 amplification | Dasatinib | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (5)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00470054 | Trial eligibility (AACT) |
| NCT00436605 | Trial eligibility (AACT) |
| NCT00859937 | Trial eligibility (AACT) |
| NCT00504153 | Trial eligibility (AACT) |
| NCT00423735 | Trial outcomes (AACT) |
Target-disease associations (362)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ALDH18A1-related de Barsy syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Acanthamoeba keratitis | disorder of visual system | Mouse knockout (IMPC) |
| Age-related cataract | disorder of visual system | Literature (Europe PMC) |
| Age-related cortical cataract | disorder of visual system | Variant curation (ClinVar / EVA) |
| Age-related nuclear cataract | disorder of visual system | Mouse knockout (IMPC) |
Showing 5 of 362 associations.
Vendor sourcing (23)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.002%). In silico tool predictions suggest damag... | View ClinVar record SCV002521112.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.722A>C (p.E241A) alteration is located in exon 3 (coding exon 3) of the EPHA2 gene. This alteration results from a A to C substitution at nucleotide po... | View ClinVar record SCV003529605.3 |
| DASA (Brazil) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | NM_004431.5(EPHA2):c.469G>A (p.Glu157Lys) is a missense variant that results in the substitution of glutamic acid with lysine. This variant is rare in popula... | View ClinVar record SCV007660938.2 |
| GeneDx Holdings Corp. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 34758253, 3045... | View ClinVar record SCV000330035.9 |
| Heidelberg University | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | PS2, PS3, PM2_supp, PP1_strong, PP4_supp | View ClinVar record SCV006550619.1 |
Showing 5 of 23 sourcing records.
Trial-cited literature (96)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| A simple guide to the use of Student's t-test, Mann-Whitney U test, Chi-squared test, and Kruskal-Wallis test in biostatistics. | BioData mining | 2025 | 35 |
| Neoantigens: promising targets for cancer therapy. | Signal transduction and targeted therapy | 2023 | 808 |
| Patient-derived xenograft models in cancer therapy: technologies and applications. | Signal transduction and targeted therapy | 2023 | 380 |
| Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. | World journal of gastrointestinal surgery | 2023 | 195 |
| CircRNAs in colorectal cancer: potential biomarkers and therapeutic targets. | Cell death & disease | 2023 | 125 |
Showing 5 of 96 papers.
Protein variant mentions (11)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.G26V | 1 | 2015 | PMID 25741868 |
| p.G391R | 1 | 2015 | PMID 25741868 |
| p.G948W | 1 | 2019 | PMID 31525139 |
| p.Q669H | 1 | 2015 | PMID 25741868 |
| p.Q968H | 1 | 2015 | PMID 25741868 |
Showing 5 of 11 variants.
Literature-extracted relations (15)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| DASATINIB | Chemical | associate |
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). | 2015 |
| Neoplasms | Disease | associate |
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers. | 2022 |
| Diabetes Mellitus, Type 2 | Disease | inhibit |
Impact of severe hypoglycemia on the heat shock and related protein response. | 2021 |
| Hypoglycemia | Disease | inhibit |
Impact of severe hypoglycemia on the heat shock and related protein response. | 2021 |
| Glioblastoma | Disease | associate |
First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose. | 2021 |
Showing 5 of 15 relation assertions.
Organizations publishing (130)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 6 | 2015 to 2021 |
| University of Pittsburgh | Academic | 6 | 2010 to 2021 |
| Dana-Farber Cancer Institute | Other | 5 | 2015 to 2021 |
| Harvard Medical School | Academic | 5 | 2016 to 2022 |
| Mass General Brigham | Hospital | 4 | 2017 to 2022 |
Showing 5 of 130 organizations.
Where EPHA2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- infectious disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
306 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.